hospital-acquired infection

Hospital-acquired infection control market reaches $16 billion

Wednesday, March 15, 2017

The global hospital-acquired infection (HAI) control market was worth about $16 billion (U.S.) in 2016, according to a new report by healthcare market research firm Kalorama Information.

Hospital Acquired Infection (HAI) Control Markets, provides market analysis for the prevention, diagnosis, and treatment segments of infections the HAI market focuses on, specifically nosocomial infections, infections that develop in patients during hospitalization or during stays at health facilities. The market figure includes testing products, device sterilization, specific cleaning products, and HAI treatments.

“The infection control market is a probable growth market for some time,” said Bruce Carlson, publisher of Kalorama Information. “There will always be a need to control these infections, as many of the bacteria that cause infection evolve and develop resistance to antimicrobials. New approaches to preventing, diagnosing, and treating such infections will be required for the long-term.”

The prevention segment of the HAI control market encompasses both sterilization and disinfection equipment. There is a growing trend for department-wide treatments and a revolving replacement rate is continuing to generate market stability. The rate of replacement for typical steam, heat or chemical sterilizers is between 8 and 11 years, which offers a stable replacement sales base. New technologies are a driving factor for growth, with increasing interest in wide-area sterilizing and disinfecting programs.

The report states that diagnosis – testing for nosocomial infections – is a fast-growing market segment. The increased awareness of infections is improving sales for the segment; admission screening and susceptibility testing are become popular choices for reducing infection risks.

As for the treatment side, the HAI control market has struggled to maintain growth with a weak development pipeline, growing generic product introductions, and growing resistance problems. However, more advanced products effective at treating serious infections demand a higher price, which is continuing to offset some market challenges.

South of the border, the U.S. Department of Health and Human Services (HHS) is committed to reducing the national rate of HAIs by demonstrating significant, quantitative, and measurable reductions in Catheter-Associated Urinary Tract Infection (CAUTI), Central Line-associated Bloodstream Infections (CLABSI), Clostridium difficile (“C. diff”), methicillin-resistant Staphylococcus aureus (MRSA), and surgical site infections.

The report provides market estimates and forecasts of the markets for the prevention, testing, and treatment of infections in healthcare surroundings, including the world revenues for 2010-2021 for hospital infection control, for hospital infection treatment, and for hospital infection prevention equipment and consumables (sterilization/disinfection). Sales information is also provided for the different market segments by primary geographic region and leading manufacturers’ shares.

Leave a Reply

Your email address will not be published. Required fields are marked *